About Cara Therapeutics
Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has Phase 3 programs ongoing for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. In addition, the Company has initiated a Phase 2/3 program of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica.
|
|
|
51-200 employees
View all Cara Therapeutics employees
|
|
Biotechnology
|
|
4 Stamford Plaza, 9th Floor, Stamford, Connecticut 06902, US
|
|
2004
|
Cara Therapeutics Alternatives
Frequently Asked Questions about Cara Therapeutics
Chris Posner is the CEO of Cara Therapeutics. To contact Chris Posner email at [email protected]. Or you may call 6105518706
The decision makers in Cara Therapeutics are Beth Weinberg, Catherine Munera, Chris Posner, etc. Click to Find Cara Therapeutics decision makers emails.
Cara Therapeutics Staff Directory
Search Cara Therapeutics Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.
